Business News • PR NewsWire • Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist

Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist

Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist

NEW HAVEN, Conn., Oct. 22, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that the first participant was dosed with BHV-3500, a third generation...

View More : https://www.prnewswire.com:443/news-releases/biohaven-receives-authorization-to-proceed-from-fda-and-doses-first-subject...

Releted News by prnewswire

BringCom And Versa Networks Demonstrate Multi-Carrier SD-WAN Exchange For Pan-Africa Services

OssDsign Announces FDA 510(k) Clearance of OSSDSIGN® Cranioplug

Reinvention, Innovation at Shanghai Jewellery Fair 2018

De courts-métrages de relations publiques sur Yamagata (version printemps et version été) sont mis en ligne pour les visiteurs internationaux

Qfix® to Unveil Latest Line of Thermoplastic Masks with Eye and Mouth Openings for Patient Comfort